Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

To Evaluate Sarilumab - SAR153191 (REGN88) - Auto-injector Device In Patients With Rheumatoid Arthritis

ClinicalTrials.gov ID: NCT02057250

Public ClinicalTrials.gov record NCT02057250. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 7, 2026, 9:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multicenter, Randomized, Open-Label, Parallel-Group Usability Study Of The Sarilumab Auto-Injector Device And A Prefilled Syringe In Patients With Moderate To Severe Active Rheumatoid Arthritis Who Are Candidates For Anti-IL6R Therapy

Study identification

NCT ID
NCT02057250
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
217 participants

Conditions and interventions

Conditions

Interventions

  • Auto-Injector Device (AID) Device
  • Hydroxychloroquine Drug
  • Leflunomide Drug
  • Methotrexate Drug
  • Pre-filled Syringe (PFS) Device
  • Sarilumab Drug
  • Sulfasalazine Drug

Device · Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 28, 2014
Primary completion
Jan 31, 2015
Completion
Feb 29, 2016
Last update posted
Jun 19, 2017

2014 – 2016

United States locations

U.S. sites
31
U.S. states
16
U.S. cities
28
Facility City State ZIP Site status
Investigational Site Number 840152 Huntsville Alabama 35801
Investigational Site Number 840221 Peoria Arizona 85381
Investigational Site Number 840226 Roseville California 95661
Investigational Site Number 840223 Boulder Colorado 80304
Investigational Site Number 840229 Miami Florida 33185
Investigational Site Number 840236 Orlando Florida 32804
Investigational Site Number 840155 Palm Harbor Florida 34684
Investigational Site Number 840220 South Miami Florida 33143
Investigational Site Number 840202 Hagerstown Maryland 21740
Investigational Site Number 840232 Flint Michigan 48504
Investigational Site Number 840233 Kalamazoo Michigan 49048
Investigational Site Number 840037 Tupelo Mississippi 38801
Investigational Site Number 840112 Lincoln Nebraska 68516
Investigational Site Number 840039 Albany New York 12208
Investigational Site Number 840224 Cincinnati Ohio 45219
Investigational Site Number 840002 Oklahoma City Oklahoma 73103
Investigational Site Number 840065 Tulsa Oklahoma 74135
Investigational Site Number 840009 Duncansville Pennsylvania 16635
Investigational Site Number 840062 Reading Pennsylvania 19611
Investigational Site Number 840016 North Charleston South Carolina 29406
Investigational Site Number 840025 Jackson Tennessee 38305
Investigational Site Number 840038 Austin Texas 78705
Investigational Site Number 840230 Carrollton Texas 75007
Investigational Site Number 840001 Dallas Texas 75231
Investigational Site Number 840020 Houston Texas 77034
Investigational Site Number 840239 Houston Texas 77034
Investigational Site Number 840241 Houston Texas 77034
Investigational Site Number 840242 Houston Texas 77034
Investigational Site Number 840069 Lubbock Texas 79424
Investigational Site Number 840074 Mesquite Texas 75150
Investigational Site Number 840237 Plano Texas 75042

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 22 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02057250, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 19, 2017 · Synced May 7, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02057250 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →